LACOG 0319

Patients diagnosed with recurrent or metastatic epidermoid carcinoma of the head and neck region, whose disease has progressed up to 6 months from the beginning of the last cycle of systemic treatment with platinum, and who are using immunotherapy (nivolumab);

Patients with primary tumors of the pharynx (oro or hypopharynx), oral cavity and larynx;